US extends expiration dates on J&J COVID vaccine to 6 months

Wednesday, July 28, 2021 | Matthew Perrone, AP Health Writer

Carlos Arrendondo
Carlos Arrendondo arrives for his appointment to get vaccinated, as banners advertise the availability of the Johnson & Johnson and Pfizer COVID-19 vaccines at a county-run vaccination site at the Eugene A. Obregon Park in Los Angeles Thursday, July 22, 2021. The top health official in Los Angeles County on Thursday implored residents to get vaccinated as the region experiences a coronavirus surge similar to last summer's. (AP Photo/Damian Dovarganes)

WASHINGTON (AP) — Federal health regulators on Wednesday again extended the expiration dates on Johnson & Johnson's COVID-19 vaccine, providing health workers with six more weeks to use millions of doses of the shot.

The Food and Drug Administration said in a letter to J&J that the shots remain safe and effective for at least six months when properly stored and refrigerated. It's the second time the FDA has extended the shelf life on the vaccines since June, when the agency said they could be used for up to 4 1/2 months. When first authorized in February, the FDA said the vaccines could be stored for three months at normal refrigeration levels.

Health authorities in many states had recently warned that they could be forced to throw out thousands of doses of the one-shot vaccine without an extension.

The change gives health providers more time to use remaining shots sitting at pharmacies, hospitals and clinics. After plateauing earlier this summer, vaccination rates have begun climbing again as the contagious delta variant surges across many parts of the country.

Vaccine expiration dates are based on information from drugmakers on how long the shots stay at the right strength. J&J previously stated that it continues to conduct stability testing with the aim of further extending the shelf life of the shots.

The FDA has been reviewing expiration dates on all three U.S.-authorized vaccines as companies have continued to test batches in the months since the shots first rolled out. Vaccines from Pfizer and Moderna, authorized in December, have a six-month shelf life.

J&J’s vaccine was highly anticipated because of its one-and-done formulation and easy-to-ship refrigeration.

But rival drugmakers Pfizer and Moderna, which started shipping shots months earlier, have already supplied more than enough doses to vaccinate all eligible Americans. More than 150 million Americans have been fully vaccinated with the companies’ two-dose shots. By comparison, just 13 million Americans have been vaccinated with the J&J shot.

Use of J&J’s vaccine has been hurt by several rare potential side effects. Earlier this month, U.S. health regulators added a new warning to the vaccine about links to a potentially dangerous neurological reaction called Guillain-Barré syndrome.

That followed a pause in the use of the shot in April after it was linked to a rare blood clot disorder. In both cases, government health advisers said the overall benefits of the shot still greatly outweigh the risks.

___

The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Department of Science Education. The AP is solely responsible for all content.

Should you invest $1,000 in Johnson & Johnson right now?

Before you consider Johnson & Johnson, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Johnson & Johnson wasn't on the list.

While Johnson & Johnson currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The 5 Stocks Here

 


Companies Mentioned in This Article

CompanyMarketRank™Current PricePrice ChangeDividend YieldP/E RatioConsensus RatingConsensus Price Target
Johnson & Johnson (JNJ)2.4$165.42+0.4%2.56%24.88Buy$190.38
Compare These Stocks  Add These Stocks to My Watchlist 

MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.